CLAIMS

1. A stable liquid formulation of purified hemopexin comprising:
    (a) a hemopexin content of 75 to 200 mg/mL;
    (b) from 15 mM to 200 mM citrate phosphate buffer;
    (c) a pH from 7.0 to 7.6; and
    (d) from 150 to 250 mM sodium chloride.

2. The stable liquid formulation of claim 1, comprising 15 mM citrate phosphate and 150 mM sodium chloride.

3. The stable liquid formulation of claims 1 or 2, wherein the pH is 7.2.

4. The stable liquid formulation of any one of claims 1 to 3, further comprising a non-ionic detergent.

5. The stable liquid formulation of claim 4, wherein the non-ionic detergent is polysorbate 80.

6. The stable liquid formulation of claims 4 or 5, wherein the non-ionic detergent is present in an amount of at least 0.0005% v/v.

7. The stable liquid formulation of claim 6, wherein the non-ionic detergent is present in an amount of less than 0.01% v/v.

8. The stable liquid formulation of any one of claims 1 to 7, comprising a viscosity of less than 20 mPa*S when measured at 25 °C

9. The stable liquid formulation of any one of claims 1 to 8, wherein the purified hemopexin comprises at least 95%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5% by weight of total protein as determined by measuring the hemopexin content by immunonephelometry and the total protein content by the Bradford method or UV spectroscopy at 280nm.

10. The stable liquid formulation of any one of claims 1 to 9, wherein the purified hemopexin is derived from human plasma, or is selected from the group consisting of a recombinant hemopexin, or a fusion protein comprising hemopexin.

11. The stable liquid formulation of claim 10, wherein the purified hemopexin is recovered from a plasma fraction derived from at least 500 kg of human plasma.

12. The stable liquid formulation of any one of claims 1 to 11, comprising at least 70% hemopexin monomers when stored at 37 °C for 1 month.

13. The stable liquid formulation of any one of claims 1 to 11, comprising at least 50% hemopexin monomers when stored at 37 °C for 2 months.

14. The stable liquid formulation of any one of claims 1 to 11, comprising at least 50% hemopexin monomers when stored at 37 °C for 3 months.

15. The stable liquid formulation of claim 12, comprising at least 80% hemopexin monomers when stored at 37 °C for 1 month.

16. The stable liquid formulation of claim 13, comprising at least 70% hemopexin monomers when stored at 37 °C for 2 months.

17. The stable liquid formulation of claim 14, comprising at least 60% hemopexin monomers when stored at 37 °C for 3 months.

18. Use of the stable liquid formulation of any one of claims 1 to 17 in the manufacture of a medicament for treating a condition associated with haemolysis in a subject in need thereof.

19. The use of claim 18, wherein the condition associated with haemolysis is selected from an acute haemolytic condition and/or a chronic haemolytic condition.

20. The use of claim 18, wherein the condition is selected from the group consisting of haemolytic anaemia, aplastic crisis, hyper-haemolytic crisis, transfusion-induced haemolysis, haemolytic uraemic syndrome, myocardial infarcts, acute chest syndrome, pulmonary hypertension, leg ulcers, growth retardation, bone infarcts, pre-eclampsia, renal failure, acute kidney injury, acute respiratory distress syndrome (ARDS), stroke including haemorrhagic stroke, intra-cranial haemorrhage (ICH), splenic sequestration, splenic infarcts, an autoimmune disease including autoimmune haemolytic anaemia, microbial infection or increased susceptibility to infection, malaria infection, trauma, a transplant related condition, open heart surgery using cardiopulmonary bypass, and burns, including in the treatment of haemoglobinemia or haemoglobinuria accompanied with haemolysis after a burn.

21. The use of claim 18, wherein the condition is selected from the group consisting of sickle cell anaemia, hereditary spherocytosis, hereditary elliptocytosis, thalassemia, congenital dyserythropoietic anemia and paroxysmal nocturnal haemoglobinuria (PNH), systemic lupus erythematosus and chronic lymphocytic leukemia.

22. The use of claim 18, wherein the condition is selected from the group consisting of haemorrhagic stroke and intra-cranial haemorrhage (ICH).

23. The use of claim 18, wherein the condition is ARDS.

24. The use of any one of claims 18 to 23, wherein the stable liquid formulation is formulated for administration intravenously or subcutaneously.